Trastuzumab cardiac toxicity: a problem we put our heart into

Tumori
Giacomo BregniSerena Di Cosimo

Abstract

Trastuzumab has gained a central role in the treatment of HER2-positive breast cancer, revolutionizing care in this setting. However, since the beginning of its use there have been concerns about its cardiac safety. Trastuzumab can give rise to cardiac toxicity, in some cases leading to discontinuation of treatment. Growing evidence shows that trastuzumab toxicity can be detected early or averted by means of new chemotherapy regimens using different anthracycline formulations or avoiding anthracyclines altogether. Moreover, patients in whom cardiac toxicity develops can be treated effectively and full cardiac function can be restored thanks to progress in drug management. Knowing the characteristics and proper management of trastuzumab toxicity is of paramount importance to grant patients in this setting the best available treatment.

References

May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·P CarterH M Shepard
Oct 8, 1987·The New England Journal of Medicine·D J Slamon
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SeidmanDeborah Keefe
Jun 20, 2002·Proceedings of the National Academy of Sciences of the United States of America·Cemil OzcelikAlistair N Garratt
Aug 16, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Valentina GuarneriFrancisco J Esteva
Nov 14, 2008·European Journal of Heart Failure·Karl SwedbergFaiez Zannad
Apr 20, 2010·International Journal of Cardiology·Jean-Jacques MonsuezJean-Yves Artigou
Aug 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CardinaleCarlo M Cipolla
Sep 16, 2010·Nature Reviews. Cardiology·Michael S Ewer, Steven M Ewer
Feb 3, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H JoensuuM Bates
Jul 5, 2011·European Journal of Heart Failure·Antoine H Chaanine, Roger J Hajjar
Aug 11, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C SerranoS Di Cosimo
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Nov 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D RaysonD J Richel
Mar 20, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Brian Wadugu, Bernhard Kühn
Jul 23, 2013·Lancet·Aron GoldhirschUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Dec 25, 2013·The Biochemical Journal·Jijun HaoDouglas B Sawyer
Jan 10, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BaselgaM Rozencweig
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisRachel A Freedman
Mar 4, 2014·Journal of the American Heart Association·Ghideon EzazJersey Chen
Mar 1, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J BaselgaM Rozencweig

❮ Previous
Next ❯

Software Mentioned

Myocet

Related Concepts

Related Feeds

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.